NCT07059936

Brief Summary

CT imaging data and MR imaging data from liver cancer (hepatocellular carcinoma) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
350

participants targeted

Target at P75+ for all trials

Timeline
4mo left

Started Jul 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress73%
Jul 2025Sep 2026

First Submitted

Initial submission to the registry

July 1, 2025

Completed
Same day until next milestone

Study Start

First participant enrolled

July 1, 2025

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 11, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Last Updated

July 22, 2025

Status Verified

July 1, 2025

Enrollment Period

1.2 years

First QC Date

July 1, 2025

Last Update Submit

July 17, 2025

Conditions

Hepatocellular Carcinoma (HCC)

Outcome Measures

Primary Outcomes (3)

  • disease-free survival

    1 year

  • Progression-free survival

    1 year

  • overall survival

    1 year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with hepatocellular carcinoma

You may qualify if:

  • Patients were treated for hepatocellular carcinoma in Wuhan Union Hospital from July 2025 to July 2026;
  • Aged \> 18 years old;
  • At least one CT scan or MR scan before treatment;
  • Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

You may not qualify if:

  • Poor image quality;
  • Incomplete clinical data or loss of follow-up;
  • Presence of another primary malignancy other than liver cancer;
  • Unclear pathological diagnosis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Union Hospital，Tongji Medical College，Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Central Study Contacts

Lian Yang

CONTACT

18986273791yanglian@hust.edu.cn

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 1, 2025

First Posted

July 11, 2025

Study Start

July 1, 2025

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

July 22, 2025

Record last verified: 2025-07

Locations

CN(1)